Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Isarna Therapeutics Raises €5.5 Million

Published: Friday, April 25, 2014
Last Updated: Friday, April 25, 2014
Bookmark and Share
Elizabeth Czerepak joins Company’s management team as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics GmbH has announced that it has raised Euro 5.5 million ($7.6M) in equity from its current investors including AT NewTec, Global Asset Funds, and MIG Fonds.

The company has also announced that Elizabeth Czerepak has joined Isarna’s management team as Chief Financial Officer and Chief Business Officer to lead the company’s new office location in New York City.

"Isarna is committed to its leadership in TGF-β and we see Elizabeth’s addition to our management team, as well as our expansion into the U.S., as key strategic steps toward building our presence in the global biotech industry,” said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. “We are grateful for the continued support and confidence from our investors as we work to create Isarna’s future.”

“Isarna’s goal of unlocking the power of TGF-β for cancer immunotherapy and as an innovative approach for treating ocular diseases and fibrosis is tremendously exciting and I am excited to join this impressive team and make an impact toward achieving success for the company,” added Ms. Czerepak.

Elizabeth Adkins Czerepak, MBA, brings to Isarna twenty-one years of pharmaceutical and biotechnology leadership experience and nine years as a venture capital investor at JP Morgan and Bear Stearns.

Ms. Czerepak has served in executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. (CGIX), that she took public on NASDAQ and for which she raised three rounds of public financing totaling $69M.

Prior to CGI, Elizabeth worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Isarna Therapeutics Enters into a Strategic Manufacturing Agreement with Sanofi
Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna.
Friday, January 10, 2014
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos